The most common reason federal employees and clearance holders don't seek mental health treatment is the assumption that disclosure will end their career. That assumption is now substantially wrong, and the gap between the assumption and the reality costs people real years of preventable suffering.
The current federal framework — DNI Security Executive Agent Directive 4 (SEAD 4) and the broader Whole Person Concept — explicitly treats documented mental health treatment as a POSITIVE indicator: it demonstrates self-awareness, judgment, and stability. The framework was updated specifically because the prior assumption that mental health treatment was disqualifying was driving people to conceal symptoms or avoid treatment, which is the actual security risk.
SF-86 Section 21 still requires disclosure of mental health treatment in the past 7 years (with narrow exceptions for grief or family counseling). What you disclose is the FACT of treatment, not the specific clinical content. Investigators don't need to know which medications you take or what you discuss in therapy — they need to know that you're under physician care for documented diagnoses. That disclosure, with proper documentation, almost never results in clearance denial or revocation absent other concerning factors.
The clinical reality of ketamine therapy fits this framework cleanly: it's prescribed by a board-certified physician for documented diagnosed conditions, administered in structured sessions with no daily impairment, produces no cognitive effects outside session windows, has no withdrawal or dependence concerns at therapeutic intermittent dosing, and doesn't appear on standard pre-employment drug screens (it's not in the SAMHSA-5 panel). For most federal employees and contractors, the clearance disclosure obligation is real but the clearance impact is essentially zero.
